Tag Archives: Biotechnology

Brandon Stem Cell Clinic Offers Life-changing Treatment Options

TAMPA, Fla. /ScoopCloud/ -- Brandon Stem Cell Clinic (BSCC) recognizes that osteoarthritis is one of the most common joint conditions, affecting nearly 630 million people worldwide. It is commonly associated with aging but is also frequently seen in cases of overuse of joints. The growing number of cases alone prove a need for innovative and effective treatments as populations continue to age.

Because of the anti-inflammatory properties of mesenchymal stem cells, physicians are now able to minimize inflammation-related osteoarthritis pain, as well as many other degenerative diseases and conditions.

Brandon Stem Cell Clinic was founded with the mission to provide non-surgical medical treatments to individuals who suffer from acute or chronic pain as a result of an injury or a medical condition. Brandon Stem Cell Clinic relies on the natural healing power of stem cells, mesenchymal signaling cells, and blood-related proteins to treat pain at its source.

"I have been positively and directly affected by stem cell treatment. It's been life-changing for me and my family, and I know we aren't the only family who has experienced this," says Leesa Polley, founder of Brandon Stem Cell Clinic and former stem cell therapy patient.

Advancements in stem cell research have shown the blood left in the umbilical cord of a healthy, live birth contains an incredibly rich and complex combination of growth factors, proteins and stem cells. This provides a highly active regenerative mixture.

With the use of umbilical stem cells and regenerative medicine, Brandon Stem Cell Clinic can help treat conditions such as arthritis, ACL tears, orthopedic pain and fractures, disc degeneration, degenerative joint disease, meniscus tears, and more. The clinic follows FDA guidelines and regulations set forth by the American Association of Tissue Banks (AATB) regarding the handling and delivery of stem cells to patients to ensure the safety and efficiency of each treatment.

"Our team at Brandon Stem Cell Clinic can help people get back to living and doing what they love with the people they love," said Polley.

Stem cell therapy takes approximately 30 minutes from start to finish and there is little to no recovery time. Patients can see results in as little as six weeks, but the stem cells have a positive impact up to nine months.

About Brandon Stem Cell Clinic:

Brandon Stem Cell Clinic (BSCC) uses powerful and potent umbilical stem cells to help treat patients with a variety of medical conditions. We understand umbilical stem cells are the future of regenerative medicine, and strive to provide customized treatments within a compassionate, respectful, and comfortable environment.

For more information please email us at connect@brandonstemcellclinic.com, visit our website at https://brandonstemcellclinic.com/, or call us at 813-800-STEM.

For more information contact:
Leesa Polley, founder
813-800-STEM
connect@brandonstemcellclinic.com

*PHOTO link for media: https://www.Send2Press.com/300dpi/19-0812s2p-beforeafter-300dpi.jpg

*VIDEO (YouTube): https://youtu.be/vEZF04vdAeo

Brandon Stem Cell Clinic (BSCC) recognizes that osteoarthritis is one of the most common joint conditions, affecting nearly 630 million people worldwide. It is commonly associated with aging but is also frequently seen in cases of overuse of joints. The growing number of cases alone prove a need for innovative and effective treatments as populations continue to age.

Related link: https://brandonstemcellclinic.com/

New Market Research Report on Bioelectronic Medicine Forecasts $16.6B Market

SAN FRANCISCO, Calif. /ScoopCloud/ -- A newly published market research report from Neurotech Reports, the leading market intelligence firm in the neurotechnology industry, forecasts that the worldwide market for bioelectronic medicine and related technologies will reach $16.6 billion by 2025. "The Market for Bioelectronic Medicine: 2020-2025" takes an in-depth look at the technology, markets, competitors, research, and growth rates in key application areas in the years 2020 through 2025.

"Bioelectronic medicine represents one of the most promising areas of healthcare and medical technology," said James Cavuoto, editor and publisher of Neurotech Reports. "Our team of editors and market research forecasters has more experience and expertise in this area than any other market intelligence organization."

The research report forecasts U.S. and worldwide revenue, compound annual growth rates, and competitor market shares for bioelectronic medicine devices in several key indications, including inflammatory disorders, hypertension, gastrointestinal disorders, urological disorders, cardiac disorders, metabolic disorders, and ENT disorders. It features in-depth profiles of established and startup bioelectronic medicine firms and key research institutions developing new bioelectronic and neuromodulation therapies.

A unique feature of this report is that it breaks down U.S. and worldwide revenue between core applications that conform to a classic definition of bioelectronic medicine-neuromodulation that affects an end organ-and applications that conform to an expanded definition that includes neuromodulation for neurological disorders. Also highlighted in the report is detailed information on key private and public funding agencies and venture capital firms that are investing in this space.

Authors of the report include Neurotech Reports editors James Cavuoto, Jennifer French, Jeremy Koff, and Margot Puerta. Puerta is the former editor of the journal Bioelectronic Medicine. A team of prominent industry experts also contributed valuable input to the study including Tony Arnold, principal of the consulting firm Precys and former CEO of SetPoint Medical, and Victor Pikov, CEO of Medipace Inc. and former research platforms director at Galvani Bioelectronics.

The report is available through the Neurotech Reports website: http://www.neurotechreports.com/pages/mbmsumm.html.

About Neurotech Reports:

Neurotech Reports is the leading source of news and analysis specific to the neurotechnology industry. The firm publishes the monthly newsletter Neurotech Business Report, and also produces two annual investment conferences: the Neurotech Leaders Forum, now in its 19th year, and the Bioelectronic Medicine Forum, now in its second year. Neurotech Reports also offers strategic consulting services to commercial firms and research organizations in neuromodulation and bioelectronic medicine. Learn more at: http://www.neurotechreports.com/.

*VIDEO: Neurotech Reports editor James Cavuoto offered an overview of the report at the 2019 Bioelectronic Medicine Forum in New York - https://youtu.be/KHo6P-dYiYE

*IMAGE link for media: Send2Press.com/300dpi/19-0509s2p-nr-chart-300dpi.jpg
*Caption: "The Market for Bioelectronic Medicine: 2020-2025" examines core applications involving neuromodulation that affects an end organ, but also forecasts the market in an expanded definition that includes more traditional forms of neuromodulation.

A newly published market research report from Neurotech Reports, the leading market intelligence firm in the neurotechnology industry, forecasts that the worldwide market for bioelectronic medicine and related technologies will reach $16.6 billion by 2025.

Related link: http://www.neurotechreports.com/

The C Diff Foundation Has Declared an Urgent Need to Raise Clostridium difficile Infection Clinical Trial Awareness Worldwide

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Clostridioides difficile is also known as C.difficile, C.diff, CDI (Clostridioides difficile infection), CDAD (Clostridioides difficile-associated disease) and formally called Clostridium difficile.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. About 15,000 deaths were estimated to be directly attributable to C. difficile infections making it a very important cause of infectious disease death in the United States.

"The broad range of new therapies for Clostridium difficile (C.difficile) is being intensely studied in several essential global clinical trials. This continued research underpins the current clinical needs with both preventing and treating C.difficile," stated Glenn S. Tillitson, Ph.D., FRSM, FCCP.

Individuals volunteer to participate in clinical trials in hopes of improving their own health, to access treatments that might not be available otherwise, often because they are new and not yet widely available. They help others by contributing to advances in medicine. There can also be potential risks participating in clinical trials and clinical studies. All of the known risks associated with a particular trial and or study will be discussed during the informed consent process. It will be thoroughly explained in the informed consent document that a volunteer will receive from the research staff prior to participating in any study.

To learn more about clinical research (e.g., Clostridioides difficile formally Clostridium difficile, also known as C.diff. C.difficile. CDI, CDAD) visit the U.S. Food and Drug Administration https://www.fda.gov/ or telephone 1-800-835-4709, and visit https://clinicaltrials.gov/.

"Clinical trials are vital to improving our knowledge about how best to prevent and treat C. difficile infections. Informing patients of clinical trials is important, and in recent years several clinical trials have led to significant improvements in the treatments available for patients with C. difficile infections. Clinical trials are a vital way of making progress in our search for new therapies to prevent and treat a CDI," stated Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology Leeds Teaching Hospitals, Professor of Medical Microbiology University of Leeds Institute of Biomedical and Clinical Sciences, Lead on Clostridium difficile for Public Health England, UK.

About the U.S. Food and Drug Administration (FDA):

The FDA is responsible for protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; ensuring that human and veterinary drug, and vaccines and other biological products and medical devices intended for human use are safe and effective. FDA's responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.

About ClinicalTrials.gov:

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C.difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For information please visit http://www.cdifffoundation.org/.

The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Related link: https://cdifffoundation.org/

Sue Siegel to Keynote 2019 Bioelectronic Medicine Forum in NY

NEW YORK, N.Y. /ScoopCloud/ -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announces that Sue Siegel, Chief Innovation Officer at GE and CEO of GE Ventures, will keynote the 2019 Bioelectronic Medicine Forum, which takes place in New York City on April 4, 2019. The second-annual event will be held at the Millennium Broadway Hotel & Conference Center in Times Square.

Sue has more than 35 years of corporate, entrepreneurial, and venture capital experience, all geared at turning untapped potential into real value. In this role, Sue leads GE Ventures, a multimodal innovation engine focused on accelerating promising start-ups, creating and launching new companies, licensing GE's intellectual property, developing new markets, and nurturing innovative ideas into scalable initiatives both inside and outside of GE.

Sue is currently a board member at Align Technologies (ALGN), Illumina, Inc. (ILMN), and MIT's The Engine. She has been recognized in Fortune as one of "34 Leaders Who Are Changing Health Care" and as one of "The 100 Most Influential Women in Silicon Valley" by Silicon Valley Business Journal.

Other speakers at this year's event include Imran Eba, partner at Action Potential Venture Capital, Evan Norton, divisional vice president at Abbott Ventures, Jeff Erb, senior director of business development at Medtronic, Kip Ludwig, associate professor at University of Wisconsin-Madison, Elliot Krames, past president of the International Neuromodulation Society, Marom Bikson, professor of biomedical engineering at City University of New York, Shai Gozani, CEO of NeuroMetrix Inc., and Victor Pikov, a former Galvani Bioelectronics scientist and now CEO of startup Medipace Inc.

Several promising bioelectronic medicine entrepreneurs will be presenting at the meeting. These include Daniel Powell, CEO of Spark Biomedical, Thomas Oxley, CEO of Synchron Inc., developer of the Stentrode device, Jennifer Ernst, CEO of Tivic Health, Don Deyo, CEO of FemPulse LLC, Doug Adams, CEO of Qura Inc., Nader Yaghoubi, CEO of PathMaker Neurosystems Inc., and Samuel Hamner, director of technology and product marketing at Cala Health. Also presenting will be Gaurev Sharma from Battelle and Jake Zabara from the Jacob Zabara Family Foundation. Dr. Zabara was the original developer of vagus nerve stimulation for epilepsy and a cofounder of Cyberonics Inc. (now LivaNova).

Key topics will include promising indications, alliances with bio/pharm firms, regulatory and reimbursement issues, and pricing/commercialization issues.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This second-annual conference will be a key meeting place for entrepreneurs and executives helping to found this industry."

For more information on the 2019 Bioelectronic Medicine Forum, contact Neurotech Reports at (415) 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announces that Sue Siegel, Chief Innovation Officer at GE and CEO of GE Ventures, will keynote the 2019 Bioelectronic Medicine Forum, which takes place in New York City on April 4, 2019. The second-annual event will be held at the Millennium Broadway Hotel & Conference Center in Times Square.

Related link: http://www.neurotechreports.com/

Neurotech Reports Announces 2018 Investment and Management Conference for Bioelectronic Medicine

NEW YORK, N.Y. /ScoopCloud/ -- Neurotech Reports, the publisher of Neurotech Business Report newsletter, today announced the launch of the Bioelectronic Medicine Forum, the first investment and management conference for the bioelectronic medicine industry. The inaugural event will take place on March 22, 2018 at the Millennium Broadway Times Square in New York, N.Y.

Featured speakers include Gene Civillico, Ph.D., the Program Manager for the National Institute of Health's SPARC program. Also presenting is Eric Van Gieson, Ph.D., Program Manager at DARPA's Biological Technologies Office, which oversees the ElectRx program. These two U.S. government programs have funded much of the early research into bioelectronic medicine.

Sessions will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties. Attendees will hear from some of the leading researchers and entrepreneurs developing clinically and commercially promising products such as implanted vagus nerve stimulation systems to treat hypertension, and surface stimulation devices to treat a range of disorders.

Several early-stage and emerging bioelectronic medicine firms will be presenting at the conference. These include NeuSpera Medical, which is developing a unique mid-field power technology that uses the body as a waveguide to power bioelectronic devices. Also presenting is Axion Biosystems, a manufacturer of multi-well microelectronic electrode arrays, and Neuroelectrics, a Spanish firm that manufactures noninvasive stimulation and recording devices.

The conference is co-sponsored by the Feinstein Institute for Medical Research. Imran Eba of Action Potential Venture Capital, GSK's venture arm in bioelectronic medicine, will serve as a moderator. The event takes place in the same venue and one day prior to the Future Leaders Conference, which is produced and organized by BioCentury, a global leader in business intelligence for the biopharma industry. BioCentury is pleased to serve as a marketing partner of the Bioelectronic Medicine Forum.

"Bioelectronic medicine represents one of the fastest growing segments of the life sciences industry. Participants at the 2018 Bioelectronic Medicine Forum will have an opportunity to help shape the future of this exciting field," said James Cavuoto, editor and Publisher of Neurotech Business Report.

For more information, contact James Cavuoto at 415-546-1259 or visit http://www.neurotechreports.com/pages/bioelectronic-medicine-forum.html .

*PHOTO: Send2Press.com/300dpi/18-0130s2p-Gene-Civillico-300dpi.jpg

Neurotech Reports, the publisher of Neurotech Business Report newsletter, today announced the launch of the Bioelectronic Medicine Forum, the first investment and management conference for the bioelectronic medicine industry. The inaugural event will take place on March 22, 2018 at the Millennium Broadway Times Square in New York, N.Y.

Related link: http://www.neurotechreports.com/

Iron Dust from Brakes and Worldwide Magnesium Deficiencies are Contributing to Hypertension

KESWICK, Va. /ScoopCloud/ -- With 25 years of research involving primarily the cardiovascular complications of spaceflight and more recently of the moon walkers, particularly Neil Armstrong on his historic mission and James Irwin (Apollo 15), extraordinary findings were discovered. Both had vascular complications, triggered by inhalation of deadly iron-laden dust. Author Dr. William J. Rowe has applied this information as to how this can be utilized for underlying mechanisms of hypertension on earth, triggered by iron-laden brake dust.

Based on his studies of the moon walkers, primarily those of Neil Armstrong and James Irwin, Dr. William J. Rowe, former assistant clinical professor of Medicine, Medical University of Ohio at Toledo, concluded that inhalation of highly toxic lunar iron-laden dust can contribute to extraordinary hypertension.

In an editorial, published recently in the Journal of Hypertension and Management, Dr. Rowe published that iron dust inhalation contributed to Armstrong's extraordinary diastolic blood pressure ( 160/135 ) on Earth return, consistent with impairment of cardiac function; his high adrenaline -heart failure during his lunar walk, undoubtedly played a role.

On the other hand Irwin, with a history of hypertension a month before his mission (145/ 110), returned with a bicycle stress test of 275/125 after only 3 minutes of exercise; furthermore on return, Irwin showed stress test - "blue finger nails" consistent with vascular injuries.

Having supervised over 5000 hospital based symptom-limited maximum treadmill stress tests, Dr. Rowe had never seen such extraordinary vascular complications, apparently triggered by highly toxic iron-laden dust and intensified by a magnesium deficiency invariably occurring with space flight and extremely common world-wide.

Since at least a third of the world's population has hypertension - with very recent studies showing that with present guidelines, among Americans, hypertension may actually exist in a half of the population, urban pollution problems must be vigorously addressed. Also, a European study has shown that 12 year old children may have hypertension from iron inhalation with often persistence of hypertension to adulthood.

Inhalation of brake iron dust may simulate the highly toxic lunar dust inhalation with at least 90 percent of brakes made with iron. In China, Dr. Rowe's experience of having seen not over 10 cars a day in Beijing in 1988 with no obvious pollution and his return to Beijing in 2011 with inability to see the street from his 9th. Floor hotel room is very disturbing.

Furthermore the toxicity of iron brakes is growing but in comparison with global warming, there isn't the necessity of waiting 50 years before determining how great the danger might be.

This concept will be presented at the Innovate Biotech 2017, November 29, 30, Brisbane, Australia.

On Rowe's website homepage, Neil Armstrong's historical document is shown along with Irwin's "cyanotic nail beds."

For more information, visit: http://www.femsinspace.com/

*PHOTO for Media: Send2Press.com/300dpi/17-1114s2p-DrRowe-300dpi.jpg
*Photo Caption: Dr. William J. Rowe, M.D., FBIS, FACN.

With 25 years of research involving primarily the cardiovascular complications of spaceflight and more recently of the moon walkers, particularly Neil Armstrong on his historic mission and James Irwin (Apollo 15), extraordinary findings were discovered. Both had vascular complications, triggered by inhalation of deadly iron-laden dust. Author Dr. William J. Rowe has applied this information as to how this can be utilized for underlying mechanisms of hypertension on earth, triggered by iron-laden brake dust.

Related link: http://www.femsinspace.com/

ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection

SAN DIEGO, Calif. /ScoopCloud/ -- ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus's growing HTS screening collection. This collaboration, which utilized Arcus's medicinal chemistry knowledge and ChemDiv's computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.

"A best-in-class drug always starts with a great lead, and our team has learned over the years, going back to our Tularik days, that ChemDiv's libraries have been carefully designed to increase the likelihood of identifying such great leads," said Juan Jaen, President and Co-Founder of Arcus Biosciences.

Jaen added: "Arcus currently has a number of small-molecule discovery programs targeted at the regulation of several biological pathways that appear to play important roles in the suppression of effector immune (T and NK) cells. Some of these programs are already fairly mature and will be in the clinic in short order; however, some of the earlier-stage projects will benefit immensely from having access to ChemDiv's compounds.

"ChemDiv's efficiency in producing high-quality, diverse, and medicinal chemistry-friendly compound collections, coupled with their ability to resupply compounds and build upon those initial hits with their Discovery Chemistry services makes ChemDiv a partner of choice for any organization, large or small, who is looking for a partner in small-molecule drug discovery."

"We are thrilled to have the opportunity to partner with Arcus Biosciences," commented Ron Demuth, General Manager of ChemDiv, Inc. "One of the most promising companies in the very competitive immune-oncology space and one of the few companies engaged in building a broad portfolio of internally designed small-molecule drugs for use in reversing the immunosuppressive tumor microenvironment; our priority is to help our partner by providing access to all the unique features of our expanding compound collection."

About ChemDiv:
ChemDiv is a recognized global leader in discovery chemistry with one of the industry's largest, most diverse, and most productive collections of over 1,600,000 individually crafted, lead-like, drug-like small molecules. Over the past 25 years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv's integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond. More information: http://www.chemdiv.com/.

About Arcus Biosciences:
Arcus Biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco Bay area, in the heart of the world's largest biotechnology research hub. More information: https://www.arcusbio.com/

Media Contact:
Ronald Demuth
Senior VP, Corporate Development & General Manager
ChemDiv
+1(858)-794-4860x321
rdemuth@chemdiv.com

ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus's growing HTS screening collection. This collaboration, which utilized Arcus's medicinal chemistry knowledge and ChemDiv's computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.

Medical Experts Unite Regarding Health Benefits of Testosterone Therapy in Women

IRVING, Texas /ScoopCloud/ -- BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women.

The Age Management Medicine Group (AMMG) conference runs April 27-30, 2017 in Orlando, Florida. Learn more: https://www.agemed.org/.

Nine experts, from across the United States, spanning a variety of medical disciplines and specialties, will present data then defend and vet topics related to testosterone therapy in women.

They will form a consensus and present their position at the next AMMG Conference in November in Tucson, Arizona. Their work will be submitted to medical journals for publication with the goal of gaining widespread support for the use of testosterone therapy in women.

Testosterone has shown to be one of the most cardio-protective hormones and the consensus group will make recommendations that could significantly improve healthcare and reduce heart disease in women - the number one cause of death in women and men in the United States.

Most of the research commentary on BHRT focuses on the effects of testosterone therapy in men. Yet, the data is there to support the health advantages in women. Women derive many of the same benefits from testosterone therapy as men regarding muscle mass, strength, and libido. Additionally, BHRT is protective to the brain, breast, bones, and heart. It helps reverse the annoying symptoms of declining hormones like fatigue, low energy, difficulty inability to lose weight, and irritability and it can increase bone density and help prevent age-related illnesses like osteoporosis and Alzheimer's.

Click on the link below to hear Founder and CEO of BioTE(R) Medical, Gary S. Donovitz, M.D. share the truth about hormone therapy and the critical need for this consensus.

Video (YouTube): https://youtu.be/kLecmEk7Vtg

For information on the AMMG Conference visit https://www.agemed.org/.

BioTE(R) Medical was founded by physicians for physicians and is committed to excellence in educating doctors and clients about the health benefits of bioidentical hormone pellet therapy. BioTE(R) is headquartered in Irving, Texas and has thousands of certified medical practitioners nationwide. See more about BioTE at http://www.BioTEmedical.com/.

*PHOTO for media: Send2Press.com/mediaboom/17-0419s2p-Gary-Donovitz-300dpi.jpg

*Photo Caption: BioTE(R) Medical Founder and CEO, Gary S. Donovitz M.D.

BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.

Solesence and Colorescience Announce Skin Care Collaboration

ROMEOVILLE, Ill. /ScoopCloud/ -- Solesence, a skin care product manufacturer at the forefront of environmental protection technology, has announced a partnership with leading prestige beauty brand Colorescience in a special collaboration to develop products for skin care and protection. As part of their joint development and supply relationship, Solesence will use patented mineral skin care actives technology to develop sunscreen products exclusively for Colorescience.

"Colorescience is leading the fusion between color cosmetics and skin protection," stated Kevin Cureton, Vice President at Solesence. "We're thrilled to support their efforts to continue to expand their portfolio with products that enable customers to have healthy and beautiful skin."

The partnership marks the first use of Solesence's cutting-edge technology in the beauty industry.

"This collaboration is another step forward for us as we seek to strengthen the technology behind our leading color cosmetics and skin care products," stated Ted Ebel, Chief Business Officer at Colorescience. "We look forward to utilizing Solesence's groundbreaking technology to the benefit of both our customers and our investors."

About Solesence:

Solesence is a skin care product manufacturer that is changing the face of protective skin care. Using a patented technology that transforms the way mineral sunscreen actives function, Solesence provides cosmetic and skin care brands with patent-protected products that offer best-in-class UV protection, unparalleled free radical prevention, improved photo stability and superior antioxidant performance. In their mission to improve skin health across the globe, Solesence empowers brand success through innovation, enabling brands to stand out with novel claims that customers see as essential for healthy, glowing skin. Website: www.solesence.com

About Colorescience:

For over 12 years Colorescience has been blurring the lines between makeup and skincare to bring immediate beauty today while improving and protecting skin for tomorrow. Originally crafted for the most vulnerable post-procedure skin, Colorescience is trusted, recommended, and personally used by thousands of physicians. Using only substantiated ingredients in their purest form, and including them at therapeutic and dermatologist-approved levels for maximum efficacy and performance, Colorescience products have already improved millions of lives with 365-day protection from UV rays and environmental stressors. The brand's uncompromising, health-forward approach to formulations provides confidence and reassurance to women of all ages, skin types and concerns. They understand the demands women face every day and realize the needs of today's consumer: ease, health, and beauty. Colorescience is changing the way women perceive beautiful skin; because beautiful isn't just the prettiest-it's the healthiest.

Colorescience is available through a network of licensed physicians, Colorescience.com, Sephora.com, ULTA.com and a collection of prestige online and brick-and-mortar retailers.

*LOGO for media: Send2Press.com/mediaboom/17-0131s2p-solesence-300dpi.jpg

Solesence, a skin care product manufacturer at the forefront of environmental protection technology, has announced a partnership with leading prestige beauty brand Colorescience in a special collaboration to develop products for skin care and protection. As part of their joint development and supply relationship, Solesence will use patented mineral skin care actives technology to develop sunscreen products exclusively for Colorescience.